文献速递乳腺MR

联合治疗前MRI影像组学特征与肿瘤浸润淋巴细胞预测三阴性乳腺癌新辅助全身治疗反应的模型

A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.
PubMed 文献 · Eur J Radiol · 2022-02-15

该回顾性研究纳入80例活检证实的三阴性乳腺癌患者,基于治疗前动态增强MRI提取影像组学特征并结合肿瘤浸润淋巴细胞水平建模,预测新辅助全身治疗后的病理完全缓解;联合模型AUC为0.752,阳性预测值90.9%,阴性预测值81.4%。

要点

  • 联合治疗前MRI影像组学特征与肿瘤浸润淋巴细胞水平可提高预测三阴性乳腺癌新辅助全身治疗后病理完全缓解的准确性。
  • 联合模型阳性预测值90.9%、阴性预测值81.4%,AUC为0.752,高于单独影像组学模型和单独肿瘤浸润淋巴细胞模型。
  • 影像组学模型入选特征为体积、均匀性、峰值时间点方差、同质性和方差。

核心结论

  • 联合治疗前MRI影像组学特征与治疗前粗针活检肿瘤浸润淋巴细胞水平的预测模型,提高了预测三阴性乳腺癌患者新辅助全身治疗后病理完全缓解的准确性。

研究设计与样本

  • 经机构审查委员会批准的回顾性研究,纳入80例活检证实的三阴性乳腺癌女性患者,均接受新辅助全身治疗、治疗前动态增强MRI及活检病理肿瘤浸润淋巴细胞评估。

诊断标准与关键数值

  • 以肿瘤浸润淋巴细胞≥20%定义为高肿瘤浸润淋巴细胞;病理完全缓解定义为术后手术标本中无浸润性癌;影像组学模型P=0.001、阳性预测值72.7%、阴性预测值72.0%;肿瘤浸润淋巴细胞模型P=0.038、阳性预测值65.5%、阴性预测值72.6%;联合模型P<0.001、阳性预测值90.9%、阴性预测值81.4%;AUC分别为肿瘤浸润淋巴细胞模型0.632、影像组学模型0.712、联合模型0.752。

临床应用与阅片要点

  • 作者认为,联合治疗前MRI影像组学特征与肿瘤浸润淋巴细胞水平可提高预测三阴性乳腺癌新辅助全身治疗后病理完全缓解的准确性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: We aimed to develop a predictive model based on pretreatment MRI radiomic features (MRIRF) and tumor-infiltrating lymphocyte (TIL) levels, an established prognostic marker, to improve the accuracy of predicting pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC) patients.

METHODS: This Institutional Review Board (IRB) approved retrospective study included a preliminary set of 80 women with biopsy-proven TNBC who underwent NAST, pretreatment dynamic contrast enhanced MRI, and biopsy-based pathologic assessment of TIL. A threshold of ≥ 20% was used to define high TIL. Patients were classified into pCR and non-pCR based on pathologic evaluation of post-NAST surgical specimens. pCR was defined as the absence of invasive carcinoma in the surgical specimen. Segmentation and MRIRF extraction were done using a Food and Drug Administration (FDA) approved software QuantX. The top five features were combined into a single MRIRF signature value.

RESULTS: Of 145 extracted MRIRF, 38 were significantly correlated with pCR. Five nonredundant imaging features were identified: volume, uniformity, peak timepoint variance, homogeneity, and variance. The accuracy of the MRIRF model, P = .001, 72.7% positive predictive value (PPV), 72.0% negative predictive value (NPV), was similar to the TIL model (P = .038, 65.5% PPV, 72.6% NPV). When MRIRF and TIL models were combined, we observed improved prognostic accuracy (P < .001, 90.9% PPV, 81.4% NPV). The models area under the receiver operating characteristic curve (AUC) was 0.632 (TIL), 0.712 (MRIRF) and 0.752 (TIL + MRIRF).

CONCLUSION: A predictive model combining pretreatment MRI radiomic features with TIL level on pretreatment core biopsy improved accuracy in predicting pCR to NAST in TNBC patients.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Jimenez, Abdelhafez, Mittendorf, et al. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol. 2022. PMID: 35193025. doi:10.1016/j.ejrad.2022.110220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。